{"analyses":[{"ciLowerLimit":"-3.51","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"11.32","groupDescription":"Stratified Analysis: The stratification factors were ECOGPS at randomization (0 vs. 1);LDH at randomization (\\<=ULNvs \\>ULN) via local laboratory test; Presence of liver metastases at enrollment (yes vs. no); Prior receipt of PCI (yes vs. no).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Difference in Overall Response Rates","paramValue":"3.90"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.86","spread":"8.86","upperLimit":"18.58","value":"13.2"},{"groupId":"OG001","lowerLimit":"12.19","spread":"12.19","upperLimit":"22.94","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"205"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants with an objective tumor response of CR or PR as determined by the investigator using RECIST v.1.1. CR was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) have a reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of target lesions, taking as reference the baseline SOD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"NUMBER","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received. Overall number analyzed is the number of participants with measurable disease at baseline, as assessed by investigator.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Confirmed ORR as Determined by the Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}